Abstract 53P
Background
Breast cancer is the predominant malignancy in Indonesia, as per recent data from The Global Cancer Observatory (GLOBOCAN) 2020. Employing a multifaceted therapeutic approach has curbed breast cancer patient mortality. Radiotherapy's pivotal role in comprehensive breast cancer care underscores its significance. This study marks the inaugural effort to assess radiotherapy utilization rate (RUR) among Indonesian breast cancer patients.
Methods
Secondary data were gathered from breast cancer patients diagnosed within Indonesian radiotherapy centers during 2019-2021. The primary goal was a pre-pandemic evaluation of radiotherapy utilization. After rigorous data cleansing, involving duplicate elimination, meticulous analysis ensued. This unveiled actual RUR (aRUR) and optimal RUR (oRUR) for this cohort. Comparative RUR assessment with global counterparts complemented the analysis.
Results
This study encompassed 11,037 breast cancer patients from 34 Indonesian radiotherapy centers. Of these, 96.8% were female, with a minority (2.6%) being male. Notably, 60.38% were diagnosed at advanced stages (Stages 3 and 4), mirroring developing nation trends. 17 radiotherapy centers met the criteria for aRUR analysis, resulting in 26.2%. For oRUR, 9 centers were suitable, indicating 66.3% (50.7% - 78.2%). Consequently, unmet RUR needs in Indonesian breast cancer patients stood at 60.4% (48.3% - 66.4%). Data from Australia's Cancer Collaboration for Cancer Outcomes, Research & Evaluation (CCORE) 2013 exhibited a higher oRUR of 83.5% (82.5% - 84.6%), attributed to significant stage distribution differences.
Conclusions
The underutilization of radiotherapy for Indonesian breast cancer patients persists. A notable disparity between oRUR and aRUR remains. Given these outcomes, imperative next steps entail delving into underlying factors fueling this gap and devising targeted strategies to mitigate the concern.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
164P - Neoadjuvant immune checkpoints inhibitors plus chemoradiotherapy for patients with locally advanced esophageal squamous cell carcinoma
Presenter: Ming-Wei Kao
Session: Poster Display
Resources:
Abstract
165P - BMI impact on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab
Presenter: Elisabeth Amadeo
Session: Poster Display
Resources:
Abstract
166P - Preoperative risk factors strongly related to early recurrence after R0 resection of gallbladder cancer
Presenter: SANGHUN LEE
Session: Poster Display
Resources:
Abstract
167P - Peripheral blood neutrophil-to-lymphocyte ratio correlated with serum IL-8 level and predict the outcome of hepatocellular carcinoma patients treated with immune-targeted combination therapy
Presenter: Xuenan Peng
Session: Poster Display
Resources:
Abstract
168P - Real-world clinicopathological characteristics and treatment patterns of esophageal cancer patients in China
Presenter: Zhihao Lu
Session: Poster Display
Resources:
Abstract
169P - Conversion response and prognostic factors in HCC patients with macrovascular invasion treated with atezolizumab plus bevacizumab
Presenter: xiaodong Zhu
Session: Poster Display
Resources:
Abstract
170P - Atezolizumab plus bevacizumab (A+B) versus lenvatinib for BCLC-B stage of patients with hepatocellular carcinoma (HCC): A large real-life worldwide population
Presenter: Francesco Vitiello
Session: Poster Display
Resources:
Abstract
171P - Retrospective study of the correlation between proteinuria and renal function in patients (pts) with unresectable hepatocellular carcinoma (uHCC) treated with atezolizumab plus bevacizumab (Atezo+Bev): ARISE study
Presenter: Kazuomi Ueshima
Session: Poster Display
Resources:
Abstract
172P - Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2-positive locally advanced/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary efficacy and safety from the phase II single-arm DESTINY-Gastric06 (DG06) trial
Presenter: Zhi Peng
Session: Poster Display
Resources:
Abstract
173P - Lenvatinib (L) versus sorafenib (S) second-line therapy in hepatocellular carcinoma (HCC) patients progressed to atezolizumab plus bevacizumab (AB)
Presenter: Mara Persano
Session: Poster Display
Resources:
Abstract